---
layout: default
title: Albuterol Sulfate 3 01Mg 2 5Ml Eqv To Albuterol
parent: 僅模型預測 (L5)
nav_order: 53
evidence_level: L5
indication_count: 0
---

# Albuterol Sulfate 3 01Mg 2 5Ml Eqv To Albuterol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Albuterol Sulfate: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Albuterol (international INN: salbutamol) is a well-established short-acting beta-2 adrenergic agonist (SABA), primarily used for bronchospasm relief in asthma and COPD.
The current Evidence Pack contains **no TxGNN predicted indications** for this drug, and the drug holds **zero Singapore registrations**,
making a complete repurposing evaluation impossible at this stage — a **Hold** decision is recommended until data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — 0 Singapore registrations on file |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no actual studies linked; model predictions not yet available |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN predictions are available for this drug under the current Evidence Pack. The mechanistic reasoning stage cannot proceed until predictions are generated.

Albuterol sulfate (3.01 mg/2.5 mL nebulizer solution) is a short-acting beta-2 adrenergic agonist with a well-characterised pharmacological profile. Its primary mechanism involves selective stimulation of β₂-adrenergic receptors, leading to bronchial smooth muscle relaxation. Should TxGNN predictions become available, mechanistic cross-indication analysis would likely explore conditions sharing adrenergic-pathway involvement — such as preterm labour (tocolysis), hyperkalaemia emergency management, or exercise-induced conditions.

Detailed mechanism of action data is not recorded in this Evidence Pack (Data Gap DG002). The DrugBank query returned one result (status: success), but a DrugBank ID was not extracted — this suggests a partial or unconfirmed match, possibly due to the highly specific formulation string used as the query key (`ALBUTEROL SULFATE 3.01MG/2.5ML EQV. TO ALBUTEROL` rather than the generic INN `albuterol` or `salbutamol`).

---

## Clinical Trial Evidence

Currently no related clinical trials linked under this Evidence Pack.

---

## Literature Evidence

Currently no related literature available under this Evidence Pack.

---

## Singapore Market Information

This drug is not currently registered in Singapore. No active HSA licences are on file (0 records).

---

## Safety Considerations

Please refer to the package insert for safety information.

> Both key warnings (DG001) and contraindications are flagged as blocking data gaps. Until the TFDA/HSA package insert is retrieved and parsed, no safety summary can be presented.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predicted indications have been generated, and all drug-level data fields (MOA, warnings, contraindications, Singapore regulatory history) are either absent or flagged as gaps — the minimum evidence threshold for a repurposing evaluation is not met.

**To proceed, the following is needed:**

- **Re-run TxGNN query** using the normalised INN `albuterol` or WHO INN `salbutamol`, rather than the full formulation string, to generate predicted indications
- **Resolve DG001 (Blocking):** Download and parse the package insert PDF from the TFDA/HSA website to extract warnings and contraindications
- **Resolve DG002 (High):** Confirm the DrugBank ID via the DrugBank API using `albuterol` or `salbutamol` as the lookup key; the current query returned a result but did not map a valid ID
- **Verify Singapore registration status** under both `albuterol sulfate` and `salbutamol` to ensure no licences are missed due to INN variant naming
- Once predictions are available, re-initiate the full evidence pipeline (clinical trials, literature, safety assessment)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

